# ICMJE DISCLOSURE FORM

Date:	_2023-4-2
Your Name:	Mingming Tang
Manuscript <sup>-</sup>	Title: Phosphoenolpyruvate carboxykinase 2 inhibits lung adenocarcinoma tumor cell immune escape
through oxid	lative stress-induced senescence as a potential therapeutic target_
Manuscript	number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	_XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	<b>X</b> None	
4	Consulting fees	<b>X</b> None	

	Payment or honoraria for lectures, presentations, speakers bureaus,	_ XNone	
	manuscript writing or educational events		
6	Payment for expert	X None	
Ū	testimony		
7	Support for attending meetings and/or travel	_ <b>X</b> None	
8	Patents planned, issued or	_ <b>X</b> None	
	pending		
-			
9	9 Participation on a Data Safety Monitoring Board or Advisory Board	_ <b>X</b> None	
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	<b>X</b> None	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	_XNone	
	financial interests		

# Please summarize the above conflict of interest in the following box:

Х

Please place an "X" next to the following statement to indicate your agreement:

\_ X \_\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

## ICMJE DISCLOSURE FORM

Date:	2023-4-2	
Your Name:	e: Jianjun Sun	
Manuscript <sup>•</sup>	t Title: Phosphoenolpyruvate carboxykinase 2 inhibits lung adenocarcinoma tumor cell immune es	cape
through oxid	ridative stress-induced senescence as a potential therapeutic target_	
Manuscript	t number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	_XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	<b>X</b> None	
4	Consulting fees	<b>X</b> None	

5	5 Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	_ <b>X</b> None	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	XNone	

# Please summarize the above conflict of interest in the following box:

Х

Please place an "X" next to the following statement to indicate your agreement:

\_ X \_\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

Date:	_2023-4-2	
Your Name:_	: Zhigang Cai	
Manuscript 1	t Title: Phosphoenolpyruvate carboxykinase 2 inhibits lung adenocarcinoma tumor cell immune esc	cape
through oxid	idative stress-induced senescence as a potential therapeutic target_	
Manuscript i	t number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	_XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	<b>X</b> None	
4	Consulting fees	<b>X</b> None	

	Payment or honoraria for lectures, presentations, speakers bureaus,	_ XNone	
	manuscript writing or educational events		
6	Payment for expert	X None	
Ū	testimony		
7	Support for attending meetings and/or travel	_ <b>X</b> None	
8	Patents planned, issued or	_ <b>X</b> None	
	pending		
-			
9	9 Participation on a Data Safety Monitoring Board or Advisory Board	_ <b>X</b> None	
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	<b>X</b> None	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	_XNone	
	financial interests		

# Please summarize the above conflict of interest in the following box:

Х

Please place an "X" next to the following statement to indicate your agreement:

\_ X \_\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.